IDO/TDO inhibition is a topic we’ve been following the progress on for several years now with various updates along the way. It’s also one of our most requested Previews for this year’s ASCO meeting taking place next month.
The Bean, Chicago
In Chicago next month, initial data from several trials is due to be presented.
- What can we expect?
- How are the main players in this landscape doing?
- Will this combination be the next big thing in the oncology IO space?
In our latest #ASCO17 Preview, we take a hard look at IDO/TDO inhibitors.
Subscribers can login to read our latest expert interview
It’s a funny old world sometimes… I was planning to post a mini series on immuno-oncology presentations from ESMO this week and review what we had learned from the new data, good and not so good. This morning’s sudden announcement from Genentech regarding their latest collaboration is therefore rather timely:
“An exclusive worldwide licensing agreement and research collaboration with NewLink Genetics for the discovery and development of IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitors for the potential treatment of cancer.”
There are a number of reasons why they might do this that make a lot of solid scientific sense.
To learn more about our insights, subscribers can log-in.